You are here

Clinical Trials: Cord Blood

Condition:   Chronic Granulomatous Disease
Interventions:   Drug: Busulfan;   Biological: Alemtuzumab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Cyclosporine;   Procedure: Stem Cell Infusion
Sponsors:   Baylor College of Medicine;   Texas Children's Hospital
Active, not recruiting - verified July 2017
Condition:   Lymphoma
Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: gemcitabine hydrochloride;   Drug: ifosfamide;   Drug: mechlorethamine hydrochloride;   Drug: melphalan;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vincristine sulfate;   Drug: vinorelbine tartrate;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsors:   Memorial Sloan Kettering Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified May 2017
Conditions:   Leukemia, Myeloid;   Leukemia;   Acute Myeloid Leukemia (AML)
Interventions:   Procedure: Allogeneic HSCT;   Drug: Anti-thymocyte globulin (ATG);   Drug: Cyclosporine (CSP);   Drug: Mycophenolate mofetil (MMF);   Radiation: Total lymphoid irradiation (TLI);   Drug: Methylprednisolone sodium succinate;   Drug: Best standard care
Sponsors:   Stanford University;   Genzyme, a Sanofi Company
Terminated
Conditions:   Leukemia;   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome
Interventions:   Drug: Clofarabine/Busulfan x 4;   Procedure: Peripheral blood stem cell transplant;   Radiation: Total Lymphoid Irradiation
Sponsors:   University of Michigan Cancer Center;   Genzyme, a Sanofi Company
Completed
Conditions:   Leukemia;   Lymphoma;   Myelodysplastic Syndromes
Interventions:   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
Active, not recruiting - verified August 2017
Conditions:   Acute Myeloid Leukemia;   Leukemia, Lymphoblastic, Acute;   Leukemia, Bilineage, Acute;   Leukemia, Myeloid, Chronic
Intervention:   Biological: Ex vivo expansion of cord blood
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Children's Cancer Foundation
Terminated
Condition:   Graft Versus Host Disease
Intervention:   Drug: Interleukin-2
Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Novartis
Active, not recruiting
Condition:   Epidermolysis Bullosa
Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Procedure: hematopoietic bone marrow transplantation
Sponsor:   Masonic Cancer Center, University of Minnesota
Terminated
Condition:   Inherited Immune Deficiencies
Interventions:   Drug: Fludarabine;   Drug: Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine;   Drug: Sirolimus or equivalent based on response;   Drug: Granulocyte Colony Stimulating Factor (G-CSF);   Other: hematopoietic progenitor cells
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 1, 2016
Conditions:   Sickle Cell Disease;   Beta Thalassemia
Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Alemtuzumab;   Procedure: Allogeneic stem cell transplant
Sponsor:   Columbia University
Recruiting - verified July 2017

Pages